PK Chemicals gains PDA approval for production of compound  

2006.01.31
PK Chemicals based in Køge, south of Copenhagen, has gained approval from PDA to produce a haemostatic compound for the US market

PK Chemicals based in Køge, south of Copenhagen, has gained approval from PDA to produce a haemostatic compound for the US market. The US company Medafor has patented the compound, and Magle Pharma, a Swedish company, owns the product while PK Chemicals has developed the systems for production and has the ingredient know-how. PK Chemicals has entered a contract with Medafor to produce the substance.

Lars Skov Ibsen, managing director of PK Chemicals comments: "We expect to be able to triple our revenues over the next four to five years". The product is expected to have great potential on the US market where hospitals in particular are seen as major purchasers, since the compound can be used to stop bleeding during surgery.

"Under a microscope, the haemostatic compound can be seen as small pellets that can draw the water out of the blood, which then turns into a rubber-like substance. It happens in milliseconds, and since it is biodegradable there are no side effects", explains Lars Skov Ibsen. Medafor plans to launch the product within the next few months. The news was reported by the business newspaper Erhvervsbladet.

Link > PK Chemicals 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×